Cytochrome P450 monooxygenase of Acanthamoeba castellanii participates in resistance to polyhexamethylene biguanide treatment

Jian-Ming Huang1, Pin-Ju Ko2, Chao-Li Huang3, Po-Wei Wen4, Chun-Hsien Chen5, Min-Hsiu Shih6, Wei-Chen Lin1,2,5,a, and Fu-Chin Huang6,a,*

1 Department of Parasitology, College of Medicine, National Cheng Kung University, Tainan 701, Taiwan
2 Department of Microbiology and Immunology, College of Medicine, National Cheng Kung University, Tainan 701, Taiwan
3 Institute of Tropical Plant Sciences and Microbiology, National Cheng Kung University, Tainan 701, Taiwan
4 School of Medicine, College of Medicine, National Cheng Kung University, Tainan 701, Taiwan
5 Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, Tainan 701, Taiwan
6 Department of Ophthalmology, National Cheng Kung University Hospital, Tainan 701, Taiwan

Received 29 June 2021, Accepted 25 October 2021, Published online 10 November 2021

Abstract – Acanthamoeba spp. are free-living parasites that can cause severe infections such as granulomatous amebic encephalitis (GAE) and amoebic keratitis (AK). Polyhexamethylene biguanide (PHMB) is a topical application for AK treatment. However, PHMB is not entirely effective against all Acanthamoeba strains or isolates. The mechanisms by which Acanthamoeba protects itself against extreme drug conditions without encystation are still unknown. According to a previous study, cytochrome P450 monooxygenase (CYP450MO) plays an important role in the oxidative biotransformation of numerous drugs related to metabolism. In this study, a CYP450MO fragment was inserted into the pGAPDH-EGFP vector and transfected into Acanthamoeba castellanii. We found that CYP450MO-overexpressing Acanthamoeba had higher survival rates than those of the control cells after PHMB treatment. Moreover, we also found that encystation-related genes such as cellulose synthase I (CSI), encystation-mediating serine proteinase (EMSP), and autophagy-related protein 8 (ATG8) expression levels were not significantly different between Acanthamoeba transfected by pGAPDH-EGFP or pGAPDH-EGFP-CYP450MO. We suggest that Acanthamoeba transfected by pGAPDH-EGFP-CYP450MO may not induce encystation-related genes to resist PHMB treatment. In conclusion, these findings indicate that CYP450MO may be an additional target when PHMB is used for treatment of amoebic keratitis.

Key words: Acanthamoeba, Polyhexamethylene biguanide, Amoebic keratitis.

Résumé – La monooxygénase du cytochrome P450 d’Acanthamoeba castellanii participe à la résistance au traitement par le polyhexaméthylène biguanide. Les Acanthamoeba spp. sont des parasites libres qui peuvent provoquer des infections graves telles que l’encéphalite amibienne granulomateuse (EAG) et la kératite amibienne (KA). Le polyhexaméthylène biguanide (PHMB) est une application topique pour le traitement de la KA. Cependant, le PHMB n’est pas entièrement efficace contre toutes les souches ou isolats d’Acanthamoeba. Les mécanismes par lesquels Acanthamoeba se protège contre des conditions médicamenteuses extrêmes sans enkystation sont encore inconnus. Selon une étude précédente, la monooxygénase du cytochrome P450 (CYP450MO) joue un rôle important dans la biotransformation oxydative de nombreux médicaments liés au métabolisme. Dans cette étude, un fragment CYP450MO a été inséré dans le vecteur pGAPDH-EGFP et transféré dans Acanthamoeba castellanii. Nous avons constaté que les Acanthamoeba surexprimant le CYP450MO avaient des taux de survie plus élevés que ceux des cellules témoins après un traitement au PHMB. De plus, nous avons également constaté que les gènes liés aux enkystations tels que la cellulose synthase I (CSI), la sérine protéinase médiatrice d’enzyme (EMSP) et les niveaux d’expression de la protéine 8 liée à l’autophagie (ATG8) n’étaient pas significativement différents entre les Acanthamoeba transférés par pGAPDH-EGFP ou par pGAPDH-EGFP-CYP450MO. Nous suggérons que les Acanthamoeba transférés par pGAPDH-EGFP-CYP450MO ne peuvent pas induire les gènes liés à l’enkystation pour résister au traitement PHMB. En conclusion, ces résultats peuvent indiquer que la monooxygénase du cytochrome P450 peut être une cible potentielle pour le traitement par PHMB de la kératite amibienne.
Introduction

*Acanthamoeba* spp. are free-living pathogenic protozoa that are distributed in several environments, including swimming lakes, pools, soil, and dust [6]. *Acanthamoeba* spp. cause severe sight-threatening infections such as granulomatous amoebic encephalitis (GAE) and amoebic keratitis (AK) [25, 37]. AK has been increasing with contact lens misuse over the past two decades [1, 4, 6, 7]. *Acanthamoeba* infects patients by causing lid edema, photophobia, epithelial defects, and ring-like stromal infiltrates through injury to the cornea [20, 24]. Patients with AK have been treated effectively over the last two decades with topical biguanides; however, current therapy requires surgical intervention because of the failure of medical treatment [15]. Polyhexamethylene biguanide (PHMB) is a polymeric biguanide used as a disinfectant and antiseptic for patients with AK [19, 22]. PHMB is effective against *Pseudomonas aeruginosa*, *Staphylococcus aureus*, *Escherichia coli*, *Candida albicans*, and *Aspergillus brasiliensis* [2, 13, 26, 38, 39]. PHMB contains highly charged positive molecules that bind to the phospholipid bilayer of the cell membrane, which is negatively charged, causing penetration, damage, cell lysis, and death of the pathogens [21]. A previous study showed that 0.01% PHMB could not induce obvious corneal toxicity but lysed *Acanthamoeba* after treatment in *vitro* [10, 22]. Combined AK treatment with propamidine, neomycin, and PHMB reduced pain in all patients within 2–4 weeks [36]. PHMB combined with H₂O₂ is also used as an ingredient in contact lens-cleaning solutions to prevent corneal infections [30]. Corneal transplantation is another therapeutic approach when topical treatment fails. Nevertheless, corneal transplantation does not eliminate all trophozoites or cysts that can grow in the new cornea. Hence, there are no clinical therapeutic approaches recommended for incorporation into standard practice.

Cytochrome P450 enzymes (CYP450s) involved in drug metabolism are widely identified in different organisms ranging from protozoa to mammals [9, 32, 40]. CYP450s bind and activate two atoms of oxygen from substrates such as peroxide, and lead to hydroxylation [3]. CYP450s also depend on monooxygenase activity, catalyzing the oxidation of endogenous and exogenous substrates, and thereby cause drug degradation [35]. The metabolism of drugs by CYP450s contributes to the formation of products that are less toxic and are excreted easily into cells. *Plasmodium berghei* and *Plasmodium falciparum* can induce CYP450s to exhibit resistance to chloroquine treatment [28]. However, clinical isolates of *Acanthamoeba* with high resistance to PHMB are associated with serious health consequences in Taiwan [10]. Therefore, cytochrome P450 monooxygenase (CYP450MO) may play an important role in the oxidative biotransformation of numerous drugs during drug metabolism in *Acanthamoeba*. In this study, we overexpressed CYP450MO in *Acanthamoeba* to investigate its effects. CYP450MO-overexpressing *Acanthamoeba* had higher survival rates than those of the control cells after PHMB treatment. We suggest that CYP450MO in *Acanthamoeba* may catalyze PHMB drug metabolism to enhance survival rates after PHMB treatment. In conclusion, these findings may help to develop potential treatments for AK patients.

Materials and methods

*Acanthamoeba castellani* cultivation

Trophozoites of *A. castellani* (Neff strain, ATCC No. 30010, Pacific Grove, CA, USA) were axenically cultured at 28 °C in peptone-yeast extract-glucose (PYG) medium (20 g/L proteose peptone, 2 g/L yeast extract, 0.1 M glucose, 4 mM MgSO₄, 3.4 mM sodium citrate, 0.9 mM Fe (NH₄)₂(SO₄)₂, 1.3 mM Na₂HPO₄, and 2 mM K₂HPO₄, pH 6.5) in cell culture flasks.

Total RNA isolation and cDNA synthesis

A total RNA Extraction Miniprep System (Viogene, Taiwan) was used to isolate RNA. The total concentration and A260/A280 ratio of mRNA were measured using ND-1000 (NanoDrop, Thermo Fisher Scientific, USA). High-capacity cDNA Reverse Transcription kits (Thermo Fisher Scientific) were used in this study. The reverse transcription conditions were set at the following times and temperatures: 25 °C for 10 min, 37 °C for 120 min, and 85 °C for 5 min; finally, the cDNA was kept at 4 °C. The reaction volume was 20 μL.

Polymerase chain reaction (PCR)

PCR products were separated on a DNA VIEW (BIO-TOOLS Co., Ltd.)–stained gel via agarose gel electrophoresis. The 18S rDNA forward primer P900 was 5'-CCC AGA TCG TTT ACC GTG AA-3', and the reverse primer R1100 was 5'-TAA ATA TTA ATG CCC CCA ACT ATC C-3', which produced 180-bp amplification bands. CSI forward primer was 5'-GGC GAA GCA CAC CTG GTT AC-3', and the reverse primer was 5'-TGC TCT ACA ACA CGG AGG TG-3', which produced 239-bp amplification bands. ATG forward primer was 5'-AAG GAA GCA CAT GAA GCT GTG G-3', and the reverse primer was 5'-CCA TCC TCG TCC TTC TAC TTG G-3', which produced 117-bp amplification bands. EMSP forward primer was 5'-CA A CT ACC CCA CCA CAC CC-3', and the reverse primer was 5'-TTT ACC GTG AA-3', which produced 360-bp amplification bands. All experiments were performed independently in triplicate. Image analysis and quantification were performed using the SmartView Pro 1200 Imager System (Major Science, USA).

Cloning of cytochrome P450 monooxygenase

Two different protocols were used to clone the CYP450MO using two vectors: the pJET1.2/blunt cloning vector and pGAPDH-EFGF vector [5]. To confirm mRNA sequencing, the amplified CYP450MO was converted to blunt-ended using Pfu S° DNA polymerase and then ligated with the pJET 1.2/blunt cloning vector. The CYP450MO sequence was amplified by PCR using the ATCC 30010 cellular cDNA as the template. To amplify the cDNA encoding CYP450MO, forward CYP450MO_F (5'-ATG CTG TGG TCG CTG ATT GTT GCG G-3') and reverse CYP450MO_R (5'-GGG
Table 1. Twenty seven related CYP450 enzymes in Acanthamoeba castellanii.

| Name           | ID       | Description                                      |
|----------------|----------|--------------------------------------------------|
| ACA1_290950    | 14926367 | cytochrome p450 superfamily protein              |
| ACA1_175170    | 14925874 | cytochrome p450 superfamily protein              |
| ACA1_174810    | 14925848 | cytochrome p450 superfamily protein              |
| ACA1_254730    | 14923340 | cytochrome p450 superfamily protein              |
| ACA1_046130    | 14922831 | cytochrome p450 superfamily protein              |
| ACA1_385730    | 14922709 | cytochrome p450 superfamily protein              |
| ACA1_183160    | 14922274 | cytochrome p450 superfamily protein              |
| ACA1_278030    | 14921744 | cytochrome p450 superfamily protein              |
| ACA1_277340    | 14921686 | cytochrome P450 monoxygenase, putative           |
| ACA1_054840    | 14921608 | cytochrome p450 superfamily protein              |
| ACA1_236320    | 14919834 | cytochrome p450 superfamily protein              |
| ACA1_372100    | 14918886 | cytochrome p450 superfamily protein              |
| ACA1_065930    | 14918208 | cytochrome p450 superfamily protein              |
| ACA1_202250    | 14916956 | cytochrome p450 superfamily protein              |
| ACA1_178260    | 14916894 | Cytochrome P450, putative                        |
| ACA1_019600    | 14915577 | cytochrome p450 superfamily protein              |
| ACA1_241260    | 14913884 | cytochrome p450 superfamily protein              |
| ACA1_100440    | 14913746 | cytochrome p450 superfamily protein              |
| ACA1_095400    | 14913279 | cytochrome p450 superfamily protein              |
| ACA1_375490    | 14912773 | cytochrome p450 superfamily protein              |
| ACA1_033760    | 14912706 | cytochrome p450 superfamily protein              |
| ACA1_353190    | 14912519 | cytochrome p450 superfamily protein              |
| ACA1_338060    | 14911366 | cytochrome p450 superfamily protein              |
| ACA1_096520    | 14913466 | cytochrome p450 superfamily protein              |
| ACA1_096500    | 14913225 | cytochrome p450 superfamily protein              |
| ACA1_374460    | 14912855 | cytochrome p450 superfamily protein              |
| ACA1_139550    | 14914785 | nadph cytochrome P450, putative                 |

CAG TGG TAC GTT TGC GGC AAA – 3’ primers were used. The CYP450MO was cloned into the pJET1.2/Mult cloning vector using a CloneJET PCR Cloning kit (Thermo Fisher Scientific). A CYP450MO fragment was inserted into the pGAPDH-EGFP vector using NdeI/SpeI sites. To amplify the cDNA encoding CYP450MO, forward NdeI_CYP450MO_F (5’ – AAC ATA TGC TGT GGT CGC TGA TTG TTG CCG – 3’) and reverse SpeI_CYP450MO_R (5’ – ACA CTA GTG GCC AGT GGT ACG TTT GCG – 3’) primers were used. All plasmids were transformed to DH5α competent E. coli for replication and construction.

Phylogenetic analysis of AccCYP450MO

We conducted blastp with the peptide sequence of AcCYP450MO against the NCBI nr database (National Center for Biotechnology Information) and retrieved the sequences of the top 100 hits. These sequences were aligned with the “hmmalign” program of the HMMER package v.3.1b2, according to the “cytochrome P450” domain in the pfam database. With the best protein substitution model “JTT + G + I” predicted by MEGA v.7.0 [17], as well as a bootstrap analysis of 100, a maximum likelihood phylogeny was reconstructed with raxml v.8.2.12 [33]. In addition, the functional domain of cytochrome P450 was predicted with the “hmmscan” program of the HMMER package. Structural similarity was assessed by an online tool “Phyre2” [14].

Cell electroporation of A. castellanii

For electroporation, cells were counted using a hemocytometer and centrifuged at 3000 rpm for 3 min to remove the medium. Acanthamoeba cells were resuspended in PAS to a final count of 5 × 10⁶ cells/mL and placed in an Eppendorf tube. Ten micrograms of plasmid DNA were added to the Eppendorf tube, followed by PAS to a final volume of 800 µL. The mixture was gently mixed and dispensed into a 4-mm cuvette. Using Gene Pulser Xcell™, the protocol was set as follows: 150 V, 10 ms. After electroporation, the cuvettes containing cells were placed on ice for 10 min, and cells were transferred to a T-75 flask containing PYG for incubation at 28 °C overnight. Stable transformants were selected using 40 µg/mL Genetin (G418).

Survival rates of CYP450MO-overexpressing A. castellanii

CYP450MO-overexpressing amoeba cells were seeded at a density of 5 × 10⁶ cells/mL in a 6-well plate and treated with 0.01% PHMB for different times, counted using a hemocytometer, and stained using trypan blue.

Statistical analysis

Data are presented as mean ± standard deviation (SD) from three independent experiments. Student’s t-test was used.
for statistical analysis. Statistical significance was set at $p < 0.05$.

**Results**

The sequencing of cytochrome P450 monooxygenase

CYP450s are widely distributed throughout different organisms ranging from protozoa to mammals [9, 32, 40]. In *Acanthamoeba*, we found 27 CYP450 enzymes (Table 1); moreover, only one CYP450 contained a monooxygenase domain (cytochrome P450 monooxygenase, ACA1_277340) to catalyze a variety of substrates with one oxygen atom [35]. To confirm the mRNA sequence of CYP450MO, we amplified the cDNA using ATCC_30010 cellular cDNA as the template. Compared to the sequences in the NCBI-nr database, we found many differences in the CYP450MO of ATCC_30010 cellular cDNA. We conducted a phylogenetic analysis on CYP450MO and the most similar peptides in GenBank. All peptides of *Acanthamoeba* formed a monophyletic clade, next to sequences of *Salpingoeca* (a Choanoflagellate) (Fig. 1). In the clade, CYP450MO was closely related to ACA1_277340 (XP004344559.1). When comparing with the coding sequence with ACA1_277340, their 5' and 3' ends were identical, while the major difference occurred in the completeness of the cytochrome P450 domain (Fig. 2). CYP450MO possessed a full structure, but the domain was truncated in ACA1_277340 (Fig. 2B). Moreover, phyre2 analysis indicated that CYP450MO showed 99.9% confidence on a high similarity to the structure of human cytochrome P450 2A6. These results indicated that CYP450MO was more likely to show full function than that of ACA1_277340.

The function of CYP450MO in *Acanthamoeba*

To determine whether CYP450MO of *Acanthamoeba* can affect PHMB drug degradation, the enzyme was overexpressed
A CYP450MO fragment was inserted into the pGAPDH-EGFP vector using NdeI/SpeI sites (Fig. 3A). After transfection in *Acanthamoeba* by electroporation for 14 days, the pGAPDH-EGFP-CYP450MO vector was expressed. To confirm that the pGAPDH-EGFP-CYP450MO vector was transfected into *Acanthamoeba*, the DNA extracted from *Acanthamoeba* was amplified using the pGAPDH-EGFP primers (Fig. 3B). The EGFP-CYP450MO fusion protein was also expressed in *Acanthamoeba* using a CellR microscope (Olympus America, Inc., USA) for 7 days (Fig. 3C).

**Figure 2.** Sequence alignment between CYP450MO and ACA1_277340. (A) Alignment of coding sequences. (B) Schematic representation of the alignment of the cytochrome P450 domain. The numbers in black indicate the position on peptides, while the numbers in grey stand for the position of the hmm model of cytochrome p450 in the pfam annotation database.

by the pGAPDH-EGFP vector. A CYP450MO fragment was inserted into the pGAPDH-EGFP vector using NdeI/SpeI sites (Fig. 3A). After transfection in *Acanthamoeba* by electroporation for 14 days, the pGAPDH-EGFP-CYP450MO vector was expressed. To confirm that the pGAPDH-EGFP-CYP450MO vector was transfected into *Acanthamoeba*, the DNA extracted from *Acanthamoeba* was amplified using the pGAPDH-EGFP primers (Fig. 3B). The EGFP-CYP450MO fusion protein was also expressed in *Acanthamoeba* using a CellR microscope (Olympus America, Inc., USA) for 7 days (Fig. 3C).

A previous study showed that clinical isolates can resist drugs by encystation to avoid environmental stress [10].
To determine whether *Acanthamoeba*-transfected pGAPDH-EGFP-CYP450MO vector induced encystations to avoid PHMB drug lysis, gene-related encystations were detected. CSI, EMSP and ATG8 identified in *Acanthamoeba* are involved in the encystation mechanism [16, 27]. The results showed that ATG8 expression was not significantly different between *Acanthamoeba*-transfected pGAPDH-EGFP and pGAPDH-EGFP-CYP450MO (Fig. 5A). CSI and EMSP expression levels were also not significantly different between *Acanthamoeba*-transfected pGAPDH-EGFP and pGAPDH-EGFP-CYP450MO.

**Figure 3.** CYP450MO overexpression in *Acanthamoeba* (ATCC_30010). (A) Schematic of the pGAPDH-EGFP-CYP450MO vector. (B) Genomic DNA of *Acanthamoeba* transfected in the pGAPDH-EGFP-CYP450MO vector detected by PCR. (C) *Acanthamoeba* transfected with pGAPDH-EGFP and pGAPDH-EGFP-CYP450MO vector (green) incubated for 7 days and examined using a fluorescence microscope.

**Figure 4.** Survival rate of *Acanthamoeba* treated with PHMB. Survival rate of *Acanthamoeba* cells transfected with pGAPDH-EGFP and pGAPDH-EGFP-CYP450MO vector incubated with 0.01% PHMB for 1, 16, and 24 h. Data are presented as mean ± standard deviation (SD).
Figs. 5B and 5C). Hence, we suggest that Acanthamoeba-transfected pGAPDH-EGFP-CYP450MO may not induce encystation to resist PHMB drug lysis.

Discussion

Acanthamoeba castellanii has 27 CYP450 genes compared to the 57 CYP450 genes in the human genome [29]. The CYP450 genes related to drug metabolism in humans are CYP2C9, CYP2C19, CYP2D6, and CYP3A4 [11]. In nematodes, Caenorhabditis elegans encodes 80 CYP450 genes. Some CYPs in C. elegans such as cyp35a2, cyp35a5, and cyp35c1 play a role in albendazole (ABZ), an anti-helminthic medication [8, 18]. However, in protozoa such as Toxoplasma gondii, the CYP450 gene exists as a single copy. The CYP450 of T. gondii plays an important role in developing resistance to drugs such as quinine, mefloquine, and clarithromycin [40]. In this study, we found 27 related CYP450 enzymes in A. castellanii (Table 1). A previous study showed that CYP450 genes in humans were observed to enhance gene diversity by alternative RNA splicing [34]. Therefore, it is likely that CYP450s are produced from the Acanthamoeba gene by alternative splicing to metabolize different drugs.

In this study, CYP450MO induced PHMB drug metabolism for the survival of Acanthamoeba, as CYP450MO overexpression enhanced the resistance of Acanthamoeba. Moreover, in previous studies, strains resistant to encystation were also transformed into pseudocysts or cysts under the effects of PHMB drug stress [10, 23]. ATG8 in Acanthamoeba encystation plays an important role in autophagy against drug therapy [12]. CSI and EMSP have also been identified in Acanthamoeba and are involved in the encystation mechanism [16, 27]. However, ATG8, CSI, and EMSP levels were not significantly different between Acanthamoeba-transfected pGAPDH-EGFP and pGAPDH-EGFP-CYP450MO (Fig. 5). Hence, we suggest that Acanthamoeba may not express encystation-related genes against PHMB drug lysis.

CYP450s are known to catalyze a variety of chemical reactions and attack substrates from electron transfer chains. On the electron transfer chains, CYP450s incorporate oxygen atoms into the substrate molecule by transferring electrons from NAD(P)H [31]. Monooxygenase systems depend on monooxygenase activity catalyzing one oxygen atom in the substrate molecule. Many drug metabolic processes catalyzed by monooxygenase involve the oxidation of endogenous and exogenous substrates [35]. In this study, we also found that the survival rates of Acanthamoeba-transfected pGAPDH-EGFP-CYP450MO vector were higher than those of the control after PHMB treatment (Fig. 4). Hence, we suggest that CYP450MO in Acanthamoeba may catalyze PHMB drug metabolism to exogenous substrates and be secreted into the extracellular environment. In the future, we aim to focus on CYP450MO as a drug target to potentially treat AK.

Conclusions

In this study, we overexpressed CYP450MO in Acanthamoeba to investigate PHMB drug resistance. Acanthamoeba
with CYP450MO-overexpression had higher survival rates than those of the control cells after PHMB treatment. We suggest that CYP450MO in Acanthamoeba may catalyze PHMB drug metabolism to enhance survival rates after PHMB treatment.

### Availability of data and materials

Data supporting the conclusions of this article are included within the article. The datasets used and/or analyzed during the present study are available from the corresponding author upon reasonable request.

### Competing interests

All authors declare that they have no conflicts of interest.

### Funding

This research was supported by the Ministry of Science and Technology (MOST) through funding to WCL (grant MOST 110-2628-B-006-32) and by the National Cheng Kung University Hospital through funding to FCH.

### Acknowledgements

We acknowledge Professor Yeonchul Hong (Department of Parasitology, Kyungpook National University School of Medicine) for providing pGAPDH-EGFP plasmid and Professor Jyh-Wei Shin (Department of Parasitology, College of Medicine, National Cheng Kung University) for providing reagents, materials, and analysis tools. We would like to thank Editage (https://www.editage.com) for English language editing.

### References

1. Allen MJ, Morby AP, White GF. 2004. Cooperativity in the binding of the cationic biocide polyhexamethylene biguanide to nucleic acids. Biomedical and Biophysical Research Communications, 318(2), 397–404.
2. Allen MJ, White GF, Morby AP. 2006. The response of Escherichia coli to exposure to the biocide polyhexamethylene biguanide. Microbiology, 152(4), 899–1000.
3. Anzenbacher P, Anzenbacherova E. 2001. Cytochromes P450 and metabolism of xenobiotics. Cellular and Molecular Life Sciences, 58(5–6), 737–747.
4. Auran JD, Starr MB, Jakobiec FA. 1987. Acanthamoeba keratitis. Cornea, 6(1), 2–26.
5. Bateman E. 2010. Expression plasmids and production of EGFP in stably transfected Acanthamoeba. Protein Expression and Purification, 70(1), 95–100.
6. Brown T, Cursons R, Keys E. 1982. Amoebae from Antarctic soil and water. Applied and Environmental Microbiology, 44c (2), 491–493.
7. Broxton P, Woodcock P, Gilbert P. 1983. A study of the antibacterial activity of some polyhexamethylene biguanides towards Escherichia coli ATCC 8739. Journal of Applied Bacteriology, 54(3), 345–353.
8. Cvilink V, Skalova L, Sztokavka B, Lamka J, Kostiainen R, Ketola RA. 2008. LC–MS–MS identification of albendazole and flubendazole metabolites formed ex vivo by Haemonchus contortus. Analytical and Bioanalytical Chemistry, 391(1), 337–343.
9. Guengerich FP. 2008. Cytochrome p450 and chemical toxicology. Chemical Research in Toxicology, 21(1), 70–83.
10. Huang F-C, Shih M-H, Chang K-F, Huang J-M, Shin J-W, Lin W-C. 2017. Characterizing clinical isolates of Acanthamoeba castellanii with high resistance to polyhexamethylene biguanide in Taiwan. Journal of Microbiology, Immunology and Infection, 50(5), 570–577.
11. Ingelman-Sundberg M. 2004. Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms. Naunyn-Schmiedeberg’s Archives of Pharmacology, 369(1), 89–104.
12. Jha BK, Jung H-J, Seo I, Kim HA, Suh S-I, Suh M-H, Baek W-K. 2014. Chloroquine has a cytotoxic effect on Acanthamoeba encystation through modulation of autophagy. Antimicrobial Agents and Chemotherapy, 58(10), 6235–6241.
13. Kamaruzzaman NF, Chong SQ, Edmondson-Brown KM, Ntow-Boahene W, Bardiau M, Good L. 2017. Bactericidal and anti-biofilm effects of polyhexamethylene Biguanide in models of intracellular and biofilm of Staphylococcus aureus isolated from bovine mastitis. Frontiers in Microbiology, 8, 1518.
14. Kelley LA, Mezulis S, Yates CM, Wass MN, Sternberg MJ. 2015. The Phyre2 web portal for protein modeling, prediction and analysis. Nature Protocols, 10(6), 845–858.
15. Kitzmann AS, Goins KM, Suphin JE, Wagoner MD. 2009. Keratothplasty for treatment of Acanthamoeba keratitis. Ophthalmology, 116(5), 864–869.
16. Kliesekova J, Kulda J, Nohynkova E. 2011. Stress-induced pseudocyst formation—a newly identified mechanism of protection against organic solvents in Acanthamoebae of the T4 genotype. Protist, 162(1), 58–69.
17. Kumar S, Stecher G, Tamura K. 2016. MEGA7: molecular evolutionary genetics analysis version 7.0 for bigger datasets. Molecular Biology and Evolution, 33(7), 1870–1874.
18. Laing ST, Ivens A, Laing R, Ravi Kumar S, Butler V, Woods DJ, Gilfeard JS. 2010. Characterization of the xenobiotic response of Caenorhabditis elegans to the anthelmintic drug albendazole and the identification of novel drug glucose metabolites. Biochemical Journal, 432(3), 505–516.
19. Larkin D, Kilvington S, Dart J. 1992. Treatment of Acanthamoeba keratitis with polyhexamethylene biguanide. Ophthalmology, 99(2), 185–191.
20. Li M-L, Shih M-H, Huang F-C, Tseng S-H, Chen C-C. 2012. Treatment of early Acanthamoeba keratitis with alcohol-assisted epithelial debridement. Cornea, 31(4), 442–446.
21. Lim N, Goh D, Bunce C, Xing W, Fraenkel G, Poole TR, Ficker L. 2008. Comparison of polyhexamethylene biguanide and chlorhexidine as monotherapy agents in the treatment of Acanthamoeba keratitis. American Journal of Ophthalmology, 145(1), 130–135.
22. Lim C-C, Peng I-C, Huang Y-H. 2020. Safety of intrastromal injection of polyhexamethylene biguanide and propamidine isethionate in a rabbit model. Journal of Advanced Research, 22, 1–6.
23. Lloyd D. 2014. Encystment in Acanthamoeba castellanii: a review. Experimental Parasitology, 145, S20–S27.
24. Lorenzo-Morales J, Khan NA, Walochnik J. 2015. An update on Acanthamoeba keratitis: diagnosis, pathogenesis and treatment. Parasite, 22, 10.
25. McCulley JP, Alizadeh H, Niederkorn JY. 1995. Acanthamoeba keratitis. Eye & Contact Lens, 21(1), 73–76.
26. Mikić IM, Cigić L, Kero D, Govorko DK, Mehić GP, Simpson P. 2018. Antimicrobial effectiveness of polyhexamethylene biguanide on Enterococcus faecalis, Staphylococcus epidermidis and Candida albicans. Medicinski Glasnik, 15(2), 132–138.
27. Moon E-K, Hong Y, Chung D-I, Kong H-H. 2012. Cysteine protease involving in autophagosomal degradation of mitochondria during encystation of *Acanthamoeba*. Molecular and Biochemical Parasitology, 185(2), 121–126.

28. Ndifor AM, Ward SA, Howells RE. 1990. Cytochrome P-450 activity in malarial parasites and its possible relationship to chloroquine resistance. Molecular and Biochemical Parasitology, 41(2), 251–257.

29. Nebert DW, Wikvall K, Miller WL. 2013. Human cytochromes P450 in health and disease. Philosophical Transactions of the Royal Society B: Biological Sciences, 368(1612), 20120431.

30. Pinna A. 2002. *Acanthamoeba* and disinfecting contact lens solutions. British Journal of Ophthalmology, 86(12), 1461–1462.

31. Porter T, Coon M. 1991. Cytochrome P-450. Multiplicity of isoforms, substrates, and catalytic and regulatory mechanisms. Journal of Biological Chemistry, 266(21), 13469–13472.

32. Seliskar M, Rozman D. 2007. Mammalian cytochromes P450 – importance of tissue specificity. Biochimica et Biophysica Acta (BBA) – General Subjects, 1770(3), 458–466.

33. Stamatakis A. 2014. RAxML version 8: a tool for phylogenetic analysis and post-analysis of large phylogenies. Bioinformatics, 30(9), 1312–1313.

34. Turman CM, Hatley JM, Ryder DJ, Ravindranath V, Strobel HW. 2006. Alternative splicing within the human cytochrome P450 superfamily with an emphasis on the brain: the convolution continues. Expert Opinion on Drug Metabolism & Toxicology, 2(3), 399–418.

35. Urlacher VB, Girhard M. 2012. Cytochrome P450 monooxygenases: an update on perspectives for synthetic application. Trends in Biotechnology, 30(1), 26–36.

36. Varga JH, Wolf TC, Jensen HG, Parmley VC, Rowsey JJ. 1993. Combined treatment of *Acanthamoeba* keratitis with propamidine, neomycin, and polyhexamethylene biguanide. American Journal of Ophthalmology, 115(4), 466–470.

37. Visvesvara GS, Moura H, Schuster FL. 2007. Pathogenic and opportunistic free-living amoebae: *Acanthamoeba* spp., *Balamuthia mandrillaris*, *Naegleria fowleri*, and *Sappinia diploidea*. FEMS Immunology & Medical Microbiology, 50(1), 1–26.

38. Walls G, Noonan L, Wilson E, Holland D, Briggs S. 2013. Successful use of locally applied polyhexamethylene biguanide as an adjunct to the treatment of fungal osteomyelitis. Canadian Journal of Infectious Diseases and Medical Microbiology, 24(2), 109–112.

39. Werthen M, Davoudi M, Sonesson A, Nitsche D, Mörgelin M, Blom K, Schlichtchen A. 2004. *Pseudomonas aeruginosa*-induced infection and degradation of human wound fluid and skin proteins ex vivo are eradicated by a synthetic cationic polymer. Journal of Antimicrobial Chemotherapy, 54(4), 772–779.

40. Zhang X, Zhang T, Liu J, Li M, Fu Y, Xu J, Liu Q. 2017. Functional characterization of a unique cytochrome P450 in *Toxoplasma gondii*. Oncotarget, 8(70), 115079.